UnknownNot Applicable

Lactobacillus Reuteri for Non-surgical Periodontal Treatment of Chronic Periodontitis With Type 2 Diabetes Patients

48 participantsStarted 2023-06-08

Plain-language summary

This study aims to investigate the clinical and microbiological efficacy of Lactobacillus reuteri as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes.

Who can participate

Age range35 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age between 35 to 70 years,
✓. type 2 diabetes with treatment ≥ 6-month, with HbA1c≤7.5%,
✓. generalized periodontitis (Stage III or IV),
✓. no less than 15 teeth

Exclusion criteria

✕. smoking, or quit smoking for less than 5 years;
✕. Suffering from other known systemic diseases that can affect the progression of periodontitis (immune abnormalities, osteoporosis, history of head and neck radiotherapy, etc.);
✕. Received periodontal treatment within 6 months;
✕. Have taken antibiotics, non-steroidal anti-inflammatory drugs, immunosuppressants, hormones and other drugs that affect periodontal within 3 months;
✕. Have taken probiotics within 6 months;
✕. Prophylactic use of antibiotics is required;
✕. Pregnant and lactating women;

What they're measuring

Probing depth

Timeframe: change from baseline to day 90

Microorganism

Timeframe: change from baseline to day 90

Trial details

NCT IDNCT05275803

SponsorThe Dental Hospital of Zhejiang University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-20

View on ClinicalTrials.gov More Periodontitis trials